Related Experiment Video
Updated: Jan 17, 2026
Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries
Published on: January 22, 2019
Discovery of novel tropomyosin receptor kinase A inhibitors by virtual screening merging ligand-based and
Xiaoman Zhao1, Yueshan Ji2, Yue Kong2
1College of Life Science and Technology, Beijing University of Chemical Technology, 15 BeiSanHuan East Road, Beijing 100029, PR China; School of Bioengineering, Beijing Polytechnic University, No.9 Liangshuihe 1st Street, Beijing 100176, PR China.
Abstract:
Tropomyosin receptor kinase (TRK) is a crucial broad-spectrum anticancer target. Its inhibitors are among the first "tumor agnostic" drugs approved for pan-cancer therapy. TRKA, a subtype of tropomyosin receptor kinase, is one of the most frequently detected in human cancers and has emerged as a key target for anticancer drug development. Our work employed a virtual screening approach integrating ligand- and structure-based strategies to identify novel inhibitors targeting TRKA. A large-scale virtual screening system was constructed for a screening database of 9.87 million commercial compounds containing a broad chemical space. A funnel-shaped multistage combinatorial screening process was adopted, with the combined time-consuming and precision of the methods in the following order: screening based on pharmacophore and shape, screening based on the QSAR model obtained from the prequel study, screening based on molecular docking, prediction of ADME properties, and patent searching. The above virtual screening system received sixteen potentially active novel inhibitors. Subsequent enzymatic activity assays revealed one hit compound ZA16 with nanomolar-level inhibitory potency, validating the efficacy of the large-scale virtual screening system. This approach can be a robust framework for guiding drug discovery and design across diverse compound libraries. Furthermore, molecular dynamics simulations revealed the interaction between this novel inhibitor and the TRKA protein domain, emphasizing the crucial role of the hydrogen bond at MET592. Through the analysis of MM/GBSA binding free energy, this study offered significant insights for drug discovery and design targeting the same protein.
Insights
Researchers identified a novel TRKA inhibitor, ZA16, using a large-scale virtual screening system. This compound shows nanomolar potency, validating the screening approach for discovering new anticancer drugs targeting TRKA.
Area of Science:
- Oncology
- Pharmacology
- Computational Chemistry
Background:
- Tropomyosin receptor kinase (TRK) inhibitors are approved as tumor-agnostic therapies.
- TRKA, a TRK subtype, is frequently detected in human cancers and is a key drug development target.
Purpose of the Study:
- To identify novel TRKA inhibitors using an integrated virtual screening approach.
- To validate the efficacy of a large-scale virtual screening system for drug discovery.
Main Methods:
- Constructed a virtual screening system for 9.87 million compounds.
- Employed a funnel-shaped multistage screening process: pharmacophore/shape, QSAR, molecular docking, ADME prediction, and patent searching.
- Utilized molecular dynamics simulations and MM/GBSA analysis to study inhibitor-protein interactions.
Main Results:
- Identified sixteen potentially active novel inhibitors.
- Discovered compound ZA16 with nanomolar inhibitory potency against TRKA.
- Revealed the critical role of a hydrogen bond at MET592 in inhibitor binding.
Conclusions:
- The large-scale virtual screening system is effective for identifying novel anticancer drug candidates.
- The identified inhibitor ZA16 and interaction insights provide a basis for TRKA-targeted drug design.
- This approach offers a robust framework for drug discovery across diverse compound libraries.
